Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial
Copyright: © 2024 Tomazini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
BACKGROUND: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.
METHODS: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19. Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. The primary outcome was the decay rate of the SARS-CoV-2 viral load logarithmic curve within 10 days after randomization.
RESULTS: From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log10 within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). There was no difference on bleeding episodes or serious adverse events at 28 days.
CONCLUSIONS: Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
PloS one - 19(2024), 2 vom: 31., Seite e0299197 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase II |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0299197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368840573 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368840573 | ||
| 003 | DE-627 | ||
| 005 | 20240229155559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0299197 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368840573 | ||
| 035 | |a (NLM)38394069 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tomazini, Bruno Martins |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2024 Tomazini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
| 520 | |a BACKGROUND: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied | ||
| 520 | |a METHODS: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19. Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. The primary outcome was the decay rate of the SARS-CoV-2 viral load logarithmic curve within 10 days after randomization | ||
| 520 | |a RESULTS: From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log10 within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). There was no difference on bleeding episodes or serious adverse events at 28 days | ||
| 520 | |a CONCLUSIONS: Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a halofuginone |2 NLM | |
| 650 | 7 | |a L31MM1385E |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Quinazolinones |2 NLM | |
| 700 | 1 | |a Tramujas, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Medrado, Fernando Azevedo |c Junior |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Samara Pinheiro do Carmo |e verfasserin |4 aut | |
| 700 | 1 | |a Negrelli, Karina Leal |e verfasserin |4 aut | |
| 700 | 1 | |a Murinize, Gabriela Souza |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Renato Hideo Nakagawa |e verfasserin |4 aut | |
| 700 | 1 | |a Vianna, Bruna Martins Pereira |e verfasserin |4 aut | |
| 700 | 1 | |a Piotto, Bruna Fornazieri |e verfasserin |4 aut | |
| 700 | 1 | |a Veiga, Thabata Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Bianca Rodrigues do |e verfasserin |4 aut | |
| 700 | 1 | |a Peneluppi Horak, Ana Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Lemos, Olivia Mora Cavalcante |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Marcela de Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Olicheski, Beatriz Baptista |e verfasserin |4 aut | |
| 700 | 1 | |a Campones, Diego Lurentt |e verfasserin |4 aut | |
| 700 | 1 | |a Peixoto, Luiz Angelo Alencar |e verfasserin |4 aut | |
| 700 | 1 | |a Basilio, Aline Dos Anjos Chaves |e verfasserin |4 aut | |
| 700 | 1 | |a Gebara, Otavio Celso Eluf |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Ana Tarina Alvarez |e verfasserin |4 aut | |
| 700 | 1 | |a Saconato, Humberto |e verfasserin |4 aut | |
| 700 | 1 | |a Valeis, Nanci |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Tamiris Abait |e verfasserin |4 aut | |
| 700 | 1 | |a Laranjeira, Ligia Nasi |e verfasserin |4 aut | |
| 700 | 1 | |a Santucci, Eliana Vieira |e verfasserin |4 aut | |
| 700 | 1 | |a Carlin, Aaron Foster |e verfasserin |4 aut | |
| 700 | 1 | |a Esko, Jeffrey David |e verfasserin |4 aut | |
| 700 | 1 | |a Gordts, Phillip Leo Stephan Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Tsimikas, Sotirios |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalcanti, Alexandre Biasi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 19(2024), 2 vom: 31., Seite e0299197 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:2 |g day:31 |g pages:e0299197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0299197 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 2 |b 31 |h e0299197 | ||